OBI Pharmaceuticals Signs Exclusive Agreement With Merck & Co. For Antibiotic Drug
OBI Pharma of Taiwan signed an agreement with MSD, known as Merck in the US, transferring exclusive rights to develop and commercialize an antibiotic drug DificidĀ® (fidaxomicin) in Taiwan to MSD. OBI Pharma will receive an initial up-front payment of $3.0 million plus royalties and milestone payments from MSD. MSD will be responsible for all future costs associated with commercialization, development, and manufacturing of Dificid in Taiwan.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.